Zoetis Inc.
Moat Score — Zoetis Inc.
Total Moat Score
17 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Zoetis holds patents on innovative products like monoclonal antibody dermatology treatments and novel parasiticides, along with deep regulatory expertise across 45+ markets, both of which create real barriers for smaller or newer entrants. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 3 / 5 | As the largest pure-play animal health company, Zoetis benefits from scale in R&D, global manufacturing (28 sites across 11 countries), and regulatory infrastructure that smaller specialists and embedded divisions of human-pharma companies struggle to match. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | Patent-protected products provide periods of genuine pricing power, but once patents expire, generic and regional manufacturers compete aggressively on price, particularly in livestock and emerging markets. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 1 / 5 | The diagnostics business creates a mild razor-and-blade dynamic (instruments driving recurring consumable revenue) but this is not a true network effect across customers. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 3 / 5 | Diagnostic instruments placed in vet clinics create moderate lock-in for consumables and service, and veterinarian prescribing habits add some stickiness, though many pharmaceutical and parasiticide products can be substituted by farmers and pet owners without great difficulty. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | Global animal health is served by a small set of scaled players (Zoetis, Elanco, Merck Animal Health, Boehringer Ingelheim, IDEXX in diagnostics), and the R&D and regulatory investment required to compete broadly limits how many companies can profitably operate at scale. |